Cost of Revenue Comparison: AstraZeneca PLC vs Perrigo Company plc

Cost of Revenue: AstraZeneca vs. Perrigo

In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. From 2014 to 2023, AstraZeneca PLC and Perrigo Company plc have shown distinct trends in their cost of revenue. AstraZeneca's cost of revenue surged by approximately 38% from 2014 to 2021, peaking in 2021 with a notable increase of over 130% compared to 2016. This reflects their strategic investments and expansion efforts. In contrast, Perrigo's cost of revenue remained relatively stable, with a modest 25% increase over the same period, indicating a consistent operational strategy.

Key Insights

• AstraZeneca's Growth: The significant rise in AstraZeneca's costs in 2021 suggests aggressive market expansion and increased production.
• Perrigo's Stability: Perrigo's steady cost pattern highlights a focus on maintaining operational efficiency.

These insights provide a window into the strategic priorities of these pharmaceutical giants, offering valuable lessons for industry stakeholders.